Physiomics plc logo

Physiomics plc (PYC)

Market Closed
12 Aug, 15:30
LSE LSE
0. 44
GBX
0
0%
GBX
1.32M Market Cap
- P/E Ratio
- Div Yield
274,963 Volume
- Eps
0.44 GBX
Previous Close
Add Transaction
Day Range
0.42 0.44
Year Range
0.25 0.8
Want to track PYC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

PYC closed today higher at 0.44 GBX, an increase of 0% from yesterday's close, completing a monthly decrease of -6.3158% or -0.03 GBX. Over the past 12 months, PYC stock gained 49.8317%.
PYC is not paying dividends to its shareholders.
The last earnings report, released on Mar 04, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Physiomics plc has completed 1 stock splits, with the recent split occurring on Dec 19, 2016.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

PYC Chart

People also search for

Eden Research PLC
2.3 GBX
-6.1224%
OBI
Ondine Biomedical Inc.
13.75 GBX
0%
OBD
Oxford Biodynamics Plc
0.13 GBX
+4%
IXI
Ixico plc
7.5 GBX
+3.4483%
FAB
Fusion Antibodies Ltd.
10.5 GBX
0%

Physiomics plc (PYC) FAQ

What is the stock price today?

The current price is 0.44 GBX.

On which exchange is it traded?

Physiomics plc is listed on LSE.

What is its stock symbol?

The ticker symbol is PYC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.32M.

Has Physiomics plc ever had a stock split?

Physiomics plc had 1 splits and the recent split was on Dec 19, 2016.

Physiomics plc Profile

Biotechnology Industry
Healthcare Sector
Dr. Peter Joseph Sargent CEO
LSE Exchange
GB00BDR6W943 ISIN
United Kingdom Country
10 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Physiomics Plc is a consulting firm that specializes in providing a range of quantitative pharmacology and computational biology services to pharmaceutical companies. Operating primarily within the United Kingdom, the United States, and the European Union including Switzerland, Physiomics combines its expertise in modeling, simulation, and data analysis to advance oncology research and development. The company leverages its proprietary Virtual Tumour predictive software to facilitate these processes. With a focus on the burgeoning field of personalized medicine, Physiomics is dedicated to developing innovative technology solutions. Founded in 2001, the company has established its headquarters in Oxford, United Kingdom, marking its place within the global pharmaceutical consulting sector.

Products and Services

Physiomics Plc offers a diversified portfolio of products and services targeted at enhancing pharmaceutical R&D through quantitative analysis and predictive modeling. These include:

  • Modeling, Simulation, and Data Analysis Services: These services are core to Physiomics' offering, encompassing a wide spectrum of oncology research and development areas. The company utilizes state-of-the-art techniques and methodologies to analyze and predict cancer treatment outcomes, thereby facilitating more efficient and effective drug development processes.
  • Virtual Tumour Predictive Software: A flagship product of Physiomics, the Virtual Tumour software is an advanced tool designed to simulate the growth and treatment of tumors in a virtual environment. This predictive modeling software aids researchers and pharmaceutical companies in understanding how different treatments might affect tumor growth and patient response, thereby streamlining the development of oncology drugs.
  • Personalized Medicine Technology Development: Recognizing the growing importance of personalized medicine, Physiomics invests in the creation of innovative technology solutions tailored to individual patient needs. These efforts aim to enhance the precision and effectiveness of treatments by considering the unique genetic, environmental, and lifestyle factors of each patient.

Contact Information

Address: Bee House
Phone: 44 123 5841575